GB0919431D0
(en)
*
|
2009-11-05 |
2009-12-23 |
Glaxosmithkline Llc |
Novel compounds
|
CN104311562B
(zh)
|
2010-05-14 |
2017-07-04 |
达那-法伯癌症研究所 |
用于治疗瘤形成、炎性疾病和其他失调的组合物和方法
|
BR112012029057A2
(pt)
|
2010-05-14 |
2020-10-13 |
Dana-Farber Cancer Institute, Inc. |
composições e métodos de tratamento de leucemia
|
CN103180318B
(zh)
|
2010-05-14 |
2017-05-10 |
达那-法伯癌症研究所 |
雄性避孕组合物以及使用方法
|
AR084070A1
(es)
|
2010-12-02 |
2013-04-17 |
Constellation Pharmaceuticals Inc |
Inhibidores del bromodominio y usos de los mismos
|
WO2012075456A1
(en)
|
2010-12-02 |
2012-06-07 |
Constellation Pharmaceuticals |
Bromodomain inhibitors and uses thereof
|
GB201106743D0
(en)
*
|
2011-04-21 |
2011-06-01 |
Glaxosmithkline Llc |
Novel compounds
|
GB201106750D0
(en)
*
|
2011-04-21 |
2011-06-01 |
Glaxosmithkline Llc |
Novel compounds
|
US9422292B2
(en)
|
2011-05-04 |
2016-08-23 |
Constellation Pharmaceuticals, Inc. |
Bromodomain inhibitors and uses thereof
|
GB201107325D0
(en)
*
|
2011-05-04 |
2011-06-15 |
Glaxosmithkline Llc |
Novel compounds
|
WO2012174487A2
(en)
|
2011-06-17 |
2012-12-20 |
Constellation Pharmaceuticals, Inc. |
Bromodomain inhibitors and uses thereof
|
GB201114103D0
(en)
*
|
2011-08-17 |
2011-09-28 |
Glaxosmithkline Llc |
Novel compounds
|
WO2013027168A1
(en)
|
2011-08-22 |
2013-02-28 |
Pfizer Inc. |
Novel heterocyclic compounds as bromodomain inhibitors
|
WO2013033269A1
(en)
*
|
2011-08-29 |
2013-03-07 |
Coferon, Inc. |
Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same
|
WO2013097052A1
(en)
*
|
2011-12-30 |
2013-07-04 |
Abbott Laboratories |
Bromodomain inhibitors
|
WO2013155695A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbott Laboratories |
Isoindolone derivatives
|
TWI602820B
(zh)
|
2012-06-06 |
2017-10-21 |
星宿藥物公司 |
溴域抑制劑及其用途
|
WO2013184878A1
(en)
|
2012-06-06 |
2013-12-12 |
Constellation Pharmaceuticals, Inc. |
Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof
|
CA2874953A1
(en)
|
2012-06-12 |
2013-12-19 |
Abbvie Inc. |
Pyridinone and pyridazinone derivatives
|
WO2013192274A2
(en)
|
2012-06-19 |
2013-12-27 |
The Broad Institute, Inc. |
Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
|
CA2895905A1
(en)
|
2012-12-21 |
2014-06-26 |
Zenith Epigenetics Corp. |
Novel heterocyclic compounds as bromodomain inhibitors
|
US9675697B2
(en)
|
2013-03-11 |
2017-06-13 |
The Regents Of The University Of Michigan |
BET bromodomain inhibitors and therapeutic methods using the same
|
US9695179B2
(en)
*
|
2013-03-14 |
2017-07-04 |
Convergene Llc |
Methods and compositions for inhibition of bromodomain-containing proteins
|
JP6280573B2
(ja)
|
2013-03-14 |
2018-02-14 |
グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited |
ブロモドメイン阻害薬としてのフロピリジン
|
WO2014159392A1
(en)
|
2013-03-14 |
2014-10-02 |
Dana-Farber Cancer Institute, Inc. |
Bromodomain binding reagents and uses thereof
|
KR101780784B1
(ko)
*
|
2013-03-14 |
2017-09-21 |
글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 |
2,3-이치환된 1-아실-4-아미노-1,2,3,4-테트라하이드로퀴놀린 유도체 및 이의 브로모도메인 억제제로서의 용도
|
UA119848C2
(uk)
|
2013-03-15 |
2019-08-27 |
Інсайт Холдинґс Корпорейшн |
Трициклічні гетероцикли як інгібітори білків бет
|
US9393232B2
(en)
|
2013-04-26 |
2016-07-19 |
Beigene, Ltd. |
Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones
|
US9636328B2
(en)
|
2013-06-21 |
2017-05-02 |
Zenith Epigenetics Ltd. |
Substituted bicyclic compounds as bromodomain inhibitors
|
BR112015031073B1
(pt)
*
|
2013-06-21 |
2022-11-29 |
Zenith Epigenetics Ltd |
Compostos inibidores bicíclicos de bromodomínio e composição farmacêutica contendo os referidos compostos
|
KR20160027062A
(ko)
*
|
2013-06-28 |
2016-03-09 |
애브비 인코포레이티드 |
브로모도메인 억제제
|
AR096758A1
(es)
*
|
2013-06-28 |
2016-02-03 |
Abbvie Inc |
Inhibidores cristalinos de bromodominios
|
US9290514B2
(en)
|
2013-07-08 |
2016-03-22 |
Incyte Holdings Corporation |
Tricyclic heterocycles as BET protein inhibitors
|
WO2015013635A2
(en)
|
2013-07-25 |
2015-01-29 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of transcription factors and uses thereof
|
KR20160038008A
(ko)
|
2013-07-31 |
2016-04-06 |
제니쓰 에피제네틱스 코포레이션 |
브로모도메인 억제제로서 신규 퀴나졸리논
|
SI3290407T1
(sl)
|
2013-10-18 |
2020-07-31 |
Celgene Quanticel Research, Inc |
Inhibitorji bromodomene
|
JP6637884B2
(ja)
|
2013-11-08 |
2020-01-29 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
ブロモドメインおよびエクストラターミナル(bet)タンパク質インヒビターを使用するがんのための併用療法
|
RU2727169C2
(ru)
*
|
2013-11-18 |
2020-07-21 |
Форма Терапеутикс Инк. |
Композиции тетрагидрохинолинов в качестве ингибиторов бромодомена вет
|
EP3071205B1
(en)
|
2013-11-18 |
2020-02-05 |
Forma Therapeutics, Inc. |
Benzopiperazine compositions as bet bromodomain inhibitors
|
US9108953B2
(en)
*
|
2013-11-26 |
2015-08-18 |
Gilead Sciences, Inc. |
Quinoline derivatives as bromodomain inhibitors
|
WO2015081189A1
(en)
|
2013-11-26 |
2015-06-04 |
Incyte Corporation |
Bicyclic heterocycles as bet protein inhibitors
|
US9399640B2
(en)
|
2013-11-26 |
2016-07-26 |
Incyte Corporation |
Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
|
US9309246B2
(en)
|
2013-12-19 |
2016-04-12 |
Incyte Corporation |
Tricyclic heterocycles as BET protein inhibitors
|
SI3092227T1
(sl)
*
|
2014-01-09 |
2018-10-30 |
Orion Corporation |
Biciklični heterociklični derivati kot zaviralci bromodomaina
|
EA038715B1
(ru)
*
|
2014-01-24 |
2021-10-08 |
Селджен Квонтисел Рисёрч, Инк. |
Ингибиторы бромодомена
|
US10793571B2
(en)
|
2014-01-31 |
2020-10-06 |
Dana-Farber Cancer Institute, Inc. |
Uses of diazepane derivatives
|
EP3099677A4
(en)
|
2014-01-31 |
2017-07-26 |
Dana-Farber Cancer Institute, Inc. |
Diaminopyrimidine benzenesulfone derivatives and uses thereof
|
CN105940005A
(zh)
|
2014-01-31 |
2016-09-14 |
达纳-法伯癌症研究所股份有限公司 |
二氮杂环庚烷衍生物及其用途
|
MX2016011160A
(es)
|
2014-02-28 |
2017-04-27 |
Tensha Therapeutics Inc |
Tratamiento de afecciones asociadas con la hiperinsulinemia.
|
JP2017511801A
(ja)
|
2014-02-28 |
2017-04-27 |
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン |
BETブロモドメイン阻害剤としての9H−ピリミド[4,5−b]インドールおよび関連類似体
|
EA039678B1
(ru)
|
2014-04-23 |
2022-02-24 |
Инсайт Корпорейшн |
1H-ПИРРОЛО[2,3-c]ПИРИДИН-7(6H)-ОНЫ И ПИРАЗОЛО[3,4-c]ПИРИДИН-7(6H)-ОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕЛКОВ BET
|
CA2952830C
(en)
|
2014-06-20 |
2022-11-01 |
Constellation Pharmaceuticals, Inc. |
Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide
|
KR20170032473A
(ko)
|
2014-08-08 |
2017-03-22 |
다나-파버 캔서 인스티튜트 인크. |
디아제판 유도체 및 그의 용도
|
MX2017001757A
(es)
|
2014-08-08 |
2017-05-30 |
Dana Farber Cancer Inst Inc |
Derivados de dihidropteridinona y sus usos.
|
JP6531167B2
(ja)
*
|
2014-09-12 |
2019-06-12 |
グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited |
ブロモドメイン阻害剤としてのテトラヒドロキノリン誘導体
|
TWI712603B
(zh)
|
2014-09-15 |
2020-12-11 |
美商英塞特公司 |
作為bet蛋白抑制劑之三環雜環
|
SG11201703414VA
(en)
|
2014-10-27 |
2017-05-30 |
Tensha Therapeutics Inc |
Bromodomain inhibitors
|
US10710992B2
(en)
|
2014-12-01 |
2020-07-14 |
Zenith Epigenetics Ltd. |
Substituted pyridinones as bromodomain inhibitors
|
US10179125B2
(en)
|
2014-12-01 |
2019-01-15 |
Zenith Epigenetics Ltd. |
Substituted pyridines as bromodomain inhibitors
|
WO2016092375A1
(en)
|
2014-12-11 |
2016-06-16 |
Zenith Epigenetics Corp. |
Substituted heterocycles as bromodomain inhibitors
|
US10231953B2
(en)
|
2014-12-17 |
2019-03-19 |
Zenith Epigenetics Ltd. |
Inhibitors of bromodomains
|
US10307407B2
(en)
|
2015-02-27 |
2019-06-04 |
The Regents Of The University Of Michigan |
9H-pyrimido [4,5-B] indoles as BET bromodomain inhibitors
|
GB201503720D0
(en)
|
2015-03-05 |
2015-04-22 |
Glaxosmithkline Ip No 2 Ltd |
Chemical compound
|
GB201504694D0
(en)
|
2015-03-19 |
2015-05-06 |
Glaxosmithkline Ip Dev Ltd |
Covalent conjugates
|
GB201504689D0
(en)
|
2015-03-19 |
2015-05-06 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
US10702517B2
(en)
|
2015-04-22 |
2020-07-07 |
Celgene Quanticel Research, Inc. |
Bromodomain inhibitor
|
TW201642860A
(zh)
*
|
2015-04-22 |
2016-12-16 |
塞爾基因定量細胞研究公司 |
布羅莫結構域抑制劑
|
WO2016196065A1
(en)
|
2015-05-29 |
2016-12-08 |
Genentech, Inc. |
Methods and compositions for assessing responsiveness of cancers to bet inhibitors
|
AU2016276963C1
(en)
|
2015-06-12 |
2021-08-05 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
WO2016203335A1
(en)
|
2015-06-18 |
2016-12-22 |
Pfizer Inc. |
Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
|
CA2989313A1
(en)
|
2015-06-26 |
2016-12-29 |
Tensha Therapeutics, Inc. |
Treatment of nut midline carcinoma
|
CN108137550A
(zh)
|
2015-08-10 |
2018-06-08 |
达纳-法伯癌症研究所有限公司 |
对bet溴结构域抑制剂的抗性的机理
|
US10428026B2
(en)
|
2015-09-02 |
2019-10-01 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Pyridinone dicarboxamide for use as bromodomain inhibitors
|
MX2018003031A
(es)
|
2015-09-11 |
2018-08-01 |
Dana Farber Cancer Inst Inc |
Ciano tienotriazolpirazinas y usos de las mismas.
|
JP2018526424A
(ja)
|
2015-09-11 |
2018-09-13 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
アセトアミドチエノトリアゾロジアゼピンおよびこれらの使用
|
WO2017050714A1
(en)
|
2015-09-22 |
2017-03-30 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Pyridinone dicarboxamide for use as bromodomain inhibitors
|
US10471050B2
(en)
|
2015-10-05 |
2019-11-12 |
Glaxosmithkline Intellectual Property (No.2) Limited |
2-OXO-1,2-dihydropyridine-3,5-dicarboxamide compounds as bromodomain inhibitors
|
US20170121347A1
(en)
|
2015-10-29 |
2017-05-04 |
Incyte Corporation |
Amorphous solid form of a bet protein inhibitor
|
RU2742035C2
(ru)
|
2015-11-25 |
2021-02-01 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Бивалентные ингибиторы бромодоменов и пути их применения
|
ES2882066T3
(es)
|
2016-02-15 |
2021-12-01 |
Univ Michigan Regents |
1,4-oxazepinas fusionadas y análogos relacionados como inhibidores de bromodominio BET
|
BR112018070549A2
(pt)
|
2016-04-06 |
2019-02-12 |
The Regents Of The University Of Michigan |
degradantes de proteína mdm2
|
WO2017176958A1
(en)
|
2016-04-06 |
2017-10-12 |
The Regents Of The University Of Michigan |
Monofunctional intermediates for ligand-dependent target protein degradation
|
CN108884083B
(zh)
|
2016-04-07 |
2022-02-25 |
葛兰素史克知识产权第二有限公司 |
作为溴结构域抑制剂的苯并[b]呋喃类化合物
|
CN108884070B
(zh)
|
2016-04-07 |
2021-07-02 |
葛兰素史克知识产权第二有限公司 |
作为溴结构域抑制剂的吡啶基衍生物
|
US10633386B2
(en)
|
2016-04-12 |
2020-04-28 |
The Regents Of The University Of Michigan |
BET protein degraders
|
PL3442972T3
(pl)
|
2016-04-15 |
2020-07-27 |
Abbvie Inc. |
Inhibitory bromodomeny
|
JP7160688B2
(ja)
*
|
2016-05-24 |
2022-10-25 |
ジェネンテック, インコーポレイテッド |
Cbp/ep300の複素環式インヒビターおよびがんの処置におけるそれらの使用
|
WO2017202742A1
(en)
|
2016-05-24 |
2017-11-30 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Pyridine dicarboxamide derivatives as bromodomain inhibitors
|
PT3472157T
(pt)
|
2016-06-20 |
2023-05-30 |
Incyte Corp |
Formas sólidas cristalinas de um inibidor bet
|
GB201614939D0
(en)
|
2016-09-02 |
2016-10-19 |
Glaxosmithkline Ip Dev Ltd |
Crystalline hydrate
|
GB201614934D0
(en)
|
2016-09-02 |
2016-10-19 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Chemical compounds
|
GB201614940D0
(en)
|
2016-09-02 |
2016-10-19 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Chemical compounds
|
EP3858837A1
(en)
|
2016-09-13 |
2021-08-04 |
The Regents of The University of Michigan |
Fused 1,4-diazepines as bet protein degraders
|
JP6961684B2
(ja)
|
2016-09-13 |
2021-11-05 |
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン |
Betタンパク質分解物質としての縮合1,4−オキサゼピン
|
CN110099685A
(zh)
*
|
2016-10-20 |
2019-08-06 |
赛尔基因光迪斯研究公司 |
溴结构域抑制剂
|
US11028051B2
(en)
*
|
2016-12-13 |
2021-06-08 |
St. Jude Children's Research Hospital |
Tetrahydroquinoline-based bromodomain inhibitors
|
US11046709B2
(en)
|
2017-02-03 |
2021-06-29 |
The Regents Of The University Of Michigan |
Fused 1,4-diazepines as BET bromodomain inhibitors
|
GB201703282D0
(en)
|
2017-03-01 |
2017-04-12 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
GB201716374D0
(en)
*
|
2017-10-06 |
2017-11-22 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
JOP20190192A1
(ar)
*
|
2017-03-01 |
2019-08-08 |
Glaxosmithkline Ip No 2 Ltd |
مشتقات بيرازول بوصفها مثبطات برومودومين
|
US11267822B2
(en)
|
2017-09-13 |
2022-03-08 |
The Regents Of The University Of Michigan |
BET bromodomain protein degraders with cleavable linkers
|
GB201716369D0
(en)
|
2017-10-06 |
2017-11-22 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
GB201716392D0
(en)
|
2017-10-06 |
2017-11-22 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
GB201814167D0
(en)
|
2018-08-31 |
2018-10-17 |
Glaxosmithkline Ip No 2 Ltd |
Compounds
|
TWI816880B
(zh)
*
|
2018-09-13 |
2023-10-01 |
大陸商恒翼生物醫藥(上海)股份有限公司 |
治療前列腺癌之組合療法
|
WO2021175432A1
(en)
|
2020-03-04 |
2021-09-10 |
Boehringer Ingelheim International Gmbh |
Method for administration of an anti cancer agent
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
WO2023041744A1
(en)
|
2021-09-17 |
2023-03-23 |
Institut Curie |
Bet inhibitors for treating pab1 deficient cancer
|
WO2023205251A1
(en)
|
2022-04-19 |
2023-10-26 |
Nuevolution A/S |
Compounds active towards bromodomains
|